Liver Involvement by Lymphoma – Indicator of Poor Response and Mortality

Kumar, Samir; Muazzam, Iqtedar A; Siddiqui, Neelam; Muzaffar, Narjis; K, Das; Awan, U.E.K.

doi:10.1016/s0923-7534(20)33656-5

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our SHL patients had a particularly poor prognosis with a median survival of 3 months and most of them died of disease within 5 months of diagnosis. These findings are similar to a previous study by Kumar et al [22]. Comprehensive staging (imaging studies and bone marrow examinations) is essential for diagnosing these patients.…”

Section: Discussionsupporting

confidence: 91%

Clinicopathologic Features of Lymphoproliferative Neoplasms Involving the Liver

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: Primary hepatic lymphoproliferative neoplasms (PHL) are uncommon. This retrospective study is aimed to present the clinicopathological characteristics of PHL and compare to secondary hepatic lymphoproliferative neoplasms (SHL). Materials and Methods: Patients who were diagnosed with lymphoproliferative neoplasms involving the liver between January 2004 and December 2018 at a tertiary medical center in central Taiwan were included. The demographic and clinical data, radiological results and histopathological findings were reviewed and summarized. Results: We analyzed 36 patients comprising 6 PHL patients and 30 SHL patients. The median age at diagnosis tended to be younger in PHL than in SHL (59 vs. 63 years old, p = 0.349). Both entities had a small male predominance. The PHL patients tended to have higher levels of aspartate aminotransferase, alanine transaminase and serum albumin and lower levels of alkaline phosphatase, total bilirubin, γ-glutamyl transferase and lactate dehydrogenase compared with SHL, but there was no significant difference. Multiple mass lesions were the most common radiological finding in both groups. Diffuse large B-cell lymphoma was the predominant subtype in both groups (67% in PHL and 40% in SHL). The PHL patients had a longer median survival than the SHL patients (not reached vs. 3 months, p = 0.003). Conclusions: Although there was no significant difference between PHL and SHL in clinical, laboratory and radiological features, the SHL patients had very poor outcomes with a median survival time of 3 months. Effective therapies are urgently required for these patients.

show abstract

Section: Discussionsupporting

confidence: 91%